Home Tools
Log in
Cart

BTK

Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development.
Signaling Pathways | Target | TargetMol
Cat. No. Product name CAS No. Purity Chemical Structure
T78782 PROTAC BTK Degrader-6 2767204-39-5 98%
PROTAC BTK Degrader-6
PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expression ...
T79019 JNJ-64264681 2101524-34-7 98%
JNJ-64264681
JNJ-64264681 is a potent, orally active, selective, and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK). This compound demonstrates favorable p...
T79113 BTK-IN-25 2562351-92-0 98%
BTK-IN-25
BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].
T79292 PROTAC BTK Degrader-5 98%
PROTAC BTK Degrader-5
PROTAC BTK Degraders-5 (Compound 3e) is a selective Bruton's tyrosine kinase (BTK) degrader with a DC50 of 7.0 nM in JeKo-1 cells, demonstrating specificity by n...
T79812 BTK-IN-27 1841502-36-0 98%
BTK-IN-27
BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM. It is...
T79841 Cinsebrutinib 2724962-58-5 98%
Cinsebrutinib
Cinsebrutinib, a Bruton's tyrosine kinase inhibitor identified as compound 5-6 in patent WO2021207549, holds potential for research in cancer treatment.
T79890 DBt-10 98%
DBt-10
DBt-10 is a potent Bruton's tyrosine kinase (BTK) degrader [1].
T82010 JDB175 2635328-79-7 98%
JDB175
JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier. It exhibits potent activity agai...
T9814 JAK3/BTK-IN-1 2674036-91-8 98%
JAK3/BTK-IN-1
JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important target...
T15365 G-744 1346669-54-2 98%
G-744
G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthriti...
T10240 ACP-5862 2230757-47-6 98%
ACP-5862
ACP-5862 is a major active and pyrrolidine ring-opened metabolite of Acalabrutinib (IC50: 5.0 nM for BTK). Acalabrutinib is an irreversible and highly selective ...
T12673L PF-06250112 1609465-89-5 98%
PF-06250112
PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM. PF-06250112 displays an inhibitory effect toward BMX nonreceptor tyrosine kinase an...
T14357 Spebrutinib besylate 1360053-81-1 98%
Spebrutinib besylate
Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).
T9813 JAK3/BTK-IN-2 2674036-93-0 98%
JAK3/BTK-IN-2
JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor. JAK3/ BTk-in-2 inhibits both BTK and JAK3, which are two important targets IN autoimmune diseases. JAK3/ BTk-in-2 ...
T16853 SB-633825 956613-01-7 98%
SB-633825
SB-633825 can inhibit cancer cell growth and angiogenesis. SB-633825 is an effective and ATP-competitive inhibitor of TIE2, LOK, and BRK (IC50s: 3.5 nM, 66 nM, 1...
T14956 CHMFL-BTK-01 2095280-64-9 98%
CHMFL-BTK-01
CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.
T16441 PCI-33380 1022899-36-0 98%
PCI-33380
PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.
T11379 GDC-0834 1133432-49-1 98%
GDC-0834
GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and r...
T6217 LFM-A13 244240-24-2 99.9%
LFM-A13
LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and...
T14681 BMS-935177 1231889-53-4 99.89%
BMS-935177
BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.
PROTAC BTK Degrader-6
T78782
PROTAC BTK Degrader-6 (Compound 15), with a DC50 of 3.18 nM, exhibits anti-inflammatory properties by inhibiting NF-κB activation and suppressing the expression ...
JNJ-64264681
T79019
JNJ-64264681 is a potent, orally active, selective, and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK). This compound demonstrates favorable p...
BTK-IN-25
T79113
BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].
PROTAC BTK Degrader-5
T79292
PROTAC BTK Degraders-5 (Compound 3e) is a selective Bruton's tyrosine kinase (BTK) degrader with a DC50 of 7.0 nM in JeKo-1 cells, demonstrating specificity by n...
BTK-IN-27
T79812
BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM. It is...
Cinsebrutinib
T79841
Cinsebrutinib, a Bruton's tyrosine kinase inhibitor identified as compound 5-6 in patent WO2021207549, holds potential for research in cancer treatment.
DBt-10
T79890
DBt-10 is a potent Bruton's tyrosine kinase (BTK) degrader [1].
JDB175
T82010
JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier. It exhibits potent activity agai...
JAK3/BTK-IN-1
T9814
JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important target...
G-744
T15365
G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthriti...
ACP-5862
T10240
ACP-5862 is a major active and pyrrolidine ring-opened metabolite of Acalabrutinib (IC50: 5.0 nM for BTK). Acalabrutinib is an irreversible and highly selective ...
PF-06250112
T12673L
PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM. PF-06250112 displays an inhibitory effect toward BMX nonreceptor tyrosine kinase an...
Spebrutinib besylate
T14357
Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).
JAK3/BTK-IN-2
T9813
JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor. JAK3/ BTk-in-2 inhibits both BTK and JAK3, which are two important targets IN autoimmune diseases. JAK3/ BTk-in-2 ...
SB-633825
T16853
SB-633825 can inhibit cancer cell growth and angiogenesis. SB-633825 is an effective and ATP-competitive inhibitor of TIE2, LOK, and BRK (IC50s: 3.5 nM, 66 nM, 1...
CHMFL-BTK-01
T14956
CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.
PCI-33380
T16441
PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.
GDC-0834
T11379
GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse and r...
LFM-A13
T6217
LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and...
BMS-935177
T14681
BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.
1 2 3 4
TargetMol